To determine the feasibility of adenoviral-mediated eNOS gene transfer into ex vivo expanded MSCs, rat MSCs (rMSCs) were isolated, expanded ex vivo, and transduced with Ad5RSVeNOS, an adenoviral vector containing the eNOS gene under the control of the Rous sarcoma virus promoter. The presence of eNOS protein in Ad5RSVeNOS-transduced rMSCs was confirmed by immunohistochemical and Western blot analysis. Transduction efficiency was dose dependent, and eNOS transgene expression in rMSCs persisted for Ն21 days in culture. The rMSCs retained multipotential differentiation capability after adenoviralmediated eNOS gene transfer. Furthermore, intracavernosal injection of Ad5RSVeNOS-transduced rMSCs increased the expression of eNOS in the corpus cavernosum, and stem cells were identified within corporal sinusoids. These findings demonstrate that replication-deficient recombinant adenovirus can be used to engineer ex vivo expanded rMSCs and that high-level eNOS transgene expression can be achieved, pointing out the clinical potential of using this novel adult stem cell-based gene therapy method for the treatment of cardiovascular diseases.
adenoviral vector; nitric oxide; gene expression; differentiation; gene therapy NITRIC OXIDE (NO) is an important molecule that regulates physiological processes, including vascular smooth muscle tone (42) . In blood vessels, NO is synthesized from L-arginine in a reaction catalyzed by endothelial NO synthase (eNOS). The NO formed in endothelial cells diffuses to neighboring vascular smooth muscle cells and activates soluble guanylyl cyclase. This activation results in increased cGMP formation, which mediates vascular smooth muscle relaxation (23, 29) . NO deficiency has been suggested to be involved in hypertension (27, 32) and erectile dysfunction (11, 12) . Therefore, the enhancement of local NO delivery is a promising therapeutic target for disease treatment. An attractive method of increasing local NO delivery is the use of gene transfer technology to increase eNOS gene expression at sites of endothelial injury. However, in vivo administration of nonviral vectors or viral vectors usually leads to low levels of gene transfer, and inasmuch as the transgene is randomly expressed in many cell types, adverse effects can occur (1, 31, 34) .
Gene-modified ex vivo expanded adult stem cells are attractive for use in gene therapy, because they avoid some of the risks and disadvantages associated with direct in vivo delivery of viral vectors, nonviral vectors, or gene-modified ex vivo expanded differentiated cells (40) . Marrow stromal cells (MSCs), also known as mesenchymal stem cells, are nonhematopoietic adult stem cells from bone marrow, are relatively easy to isolate and expand ex vivo, and have multidifferentiation potential (10, 17, 18, 21, 24, 25, 33, 38, 39, 41, 45) . Therefore, MSCs may be a useful vehicle for gene delivery in adult stem cell-based gene therapy (2, 26, 47) . For ex vivo gene transfer, adenoviral vectors have several advantages over other vectors, such as their ability to infect quiescent cells, a broad host range, the ease of preparation of high-titer viral stock, and highlevel transgene expression (9) . The objective of this study was to determine whether ex vivo expanded rat MSCs (rMSCs) can be transduced with adenovirus containing eNOS and to ascertain whether the cells retain multipotential differentiation capability after adenoviral-mediated eNOS gene transfer.
In this study, we present data demonstrating that adenoviral vectors can be used to gene engineer ex vivo expanded rMSCs and that high-level eNOS expression can be achieved, underscoring the potential utility of this novel method for adult stem cell-based gene therapy.
MATERIALS AND METHODS

Adenoviral vectors.
Ad5RSVeNOS, a replication-deficient recombinant adenovirus carrying the bovine eNOS gene un-der the control of Rous sarcoma virus (RSV) promoter, and Ad5RSVntlacZ, a replication-deficient recombinant adenovirus carrying the nuclear-targeted ␤-galactosidase reporter gene ntlacZ under the control of RSV promoter, were purchased from the University of Iowa Gene Transfer Vector Core (Iowa City, IA) (8, 20, 36, 37) . The Ad5RSVeNOS virus has a concentration of 1.2 ϫ 10 12 viral particles (vp)/ml and a titer of 3.0 ϫ 10 10 plaque-forming units (pfu)/ml. The Ad5RSVntlacZ virus has a concentration of 1.4 ϫ 10 12 vp/ml and a titer of 1.0 ϫ 10 10 pfu/ml. Isolation and ex vivo expansion of rMSCs. rMSCs were isolated as previously described (7, 30, 35, 43, 44) . Briefly, 6-wk-old male Brown Norway rats (Harlan, San Diego, CA) were euthanized with CO 2. Under sterile conditions, femurs and tibias were removed and placed in the culture medium for rMSCs [␣-MEM (GIBCO Invitrogen, Grand Island, NY), 20% fetal bovine serum (GIBCO Invitrogen), 100 U/ml penicillin, 100 g/ml streptomycin, and 25 ng/ml amphotericin B (Atlanta Biologicals, Norcross, GA), and 2 mM L-glutamine (GIBCO Invitrogen)]. Both ends of femurs and tibias were removed, and the bone marrow was flushed out using a 21-gauge needle attached to a 10-ml syringe filled with the culture medium for rMSCs. The bone marrow cells were filtered through a cell strainer with 70-m nylon mesh (BD Bioscience, Bedford, MA), and the cells from one rat were plated in a 75-cm 2 tissue culture flask (BD Bioscience). The cells were incubated in the culture medium for rMSCs at 37°C with 5% humidified CO2, and rMSCs were isolated by their adherence to tissue culture plastic. Fresh culture medium was added and replaced to remove nonadherent cells every 2-3 days. The adherent rMSCs were grown to confluency (ϳ7 days, defined as rMSCs at passage 0), harvested with 0.25% trypsin and 1 mM EDTA for 5 min at 37°C, diluted 1:3, replated in culture flasks, and again grown to confluency for further expansion. rMSCs at passage 1-5 were used for all experiments.
Transduction with adenoviral vectors. rMSCs were plated at a density of 10,000 cells/cm 2 in six-well plates or T-25 flasks (BD Bioscience) and cultured overnight. The cells were then exposed to fresh culture medium containing adenoviral vector at various multiplicities of infection (MOI, defined as pfu/cell) for 48 h. Three separate experiments were carried out, each in triplicate. Cell viability was determined using the trypan blue exclusion method.
Immunohistochemistry. Immunohistochemical analysis for eNOS transgene expression in culture was carried out as described previously (22) . Briefly, cells in six-well plates were rinsed with PBS, fixed with cold methanol (Ϫ20°C) for 5 min, and washed with PBS twice, and the immunostaining was performed using the mouse anti-eNOS monoclonal antibody (BD Transduction Laboratories, San Diego, CA; 1:100 dilution) and the mouse Immunocruz staining system (Santa Cruz Biotechnology, Santa Cruz, CA). Cells were then counterstained with hematoxylin (Rowley Biochemical, Danvers, MA), and expression of eNOS transgene in rMSCs was evaluated in situ by light microscopy scoring of cells expressing eNOS. The eNOS-positive brown cells found in two to three microscopic fields (ϫ25) were counted and expressed as a percentage of the total number of cells in those fields. Immunohistochemical analysis of eNOS-positive Ad5RSVeNOS-transduced rMSCs in rat corpus cavernosum was carried out as described above, except 5-m penile cross sections on glass slides were rinsed with PBS twice before being immunostained. Penile sections were then counterstained with hematoxylin (Rowley Biochemical), mounted with VectaMount mounting medium (Vector Laboratories, Burlingame, CA), and covered with coverslips, and the localization of eNOSpositive Ad5RSVeNOS-transduced rMSCs in rat corpus cavernosum was analyzed by light microscopy.
X-gal histochemistry for ␤-galactosidase activity. Cells in six-well plates were rinsed with PBS, fixed in a PBS solution containing 2% formaldehyde and 0.2% glutaraldehyde (Sigma, St. Louis, MO) for 5 min, washed with PBS twice, and incubated in the X-gal staining solution [5 mM K ferricyanide, 5 mM K ferrocyanide, 2 mM MgCl 2, and 1 mg/ml X-gal (Sigma), prepared in PBS] overnight at 37°C in darkness. Cells were then rinsed with PBS, and expression of ntlacZ transgene in rMSCs was evaluated by light microscopy scoring of cells expressing nuclear-targeted ␤-galactosidase activity. The ␤-galactosidase-positive blue cells found in three microscopic fields (ϫ25) were counted and expressed as a percentage of the total number of cells in those fields.
Western blot analysis. Western blot analysis for eNOS transgene expression in culture was carried out using the whole cell lysate. Briefly, cells in six-well plates or T-25 flasks were rinsed with cold PBS, drained, lysed with a buffer containing 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 0.1 mg/ml leupeptin, and 574 M phenylmethylsulfonyl fluoride (Sigma; prepared in PBS), and scraped into a 1.5-ml centrifuge tube. The sample was incubated for 45 min on ice and centrifuged at 15,000 g for 20 min, and the supernatant was collected. Protein content of the whole cell lysate was quantified colorimetrically using the bicinchoninic acid protein assay (Pierce, Rockford, IL). Whole cell lysate (5 g) was loaded onto a 4-20% Tris-glycine gel (ICN Biomedicals, Aurora, OH). After electrophoresis, the protein was transferred onto a nitrocellulose membrane by electroelution. Immunodetection was performed with mouse anti-eNOS monoclonal antibody (BD Transduction Laboratories; 1:2,500 dilution) and rabbit anti-␤-tubulin polyclonal antibody (Santa Cruz Biotechnology; 1:2,500 dilution). The secondary antibodies were horseradish peroxidase conjugated to goat anti-mouse IgG (Santa Cruz Biotechnology; 1:4,000 dilution) or antirabbit IgG (Santa Cruz Biotechnology; 1:4,000 dilution). The nitrocellulose membrane was processed using enhanced chemiluminescence Western blotting detection reagents (Amersham Pharmacia Biotech, Piscataway, NJ). Human aortic endothelial cell lysate (5 g; BD Transduction Laboratories) was used as a positive control. Western blot analysis for eNOS transgene expression in rat cavernosal tissue was carried out as described above, except 60 g of penile homogenate per lane were loaded.
In vitro differentiation of rMSCs into osteoblasts or adipocytes. In vitro differentiation of rMSCs into the osteoblast or adipocyte lineage was carried out as previously described (7, 35, 43) . Briefly, cells in six-well plates were treated with culture medium for rMSCs plus osteogenic supplement [1 ϫ 10 Ϫ5 mM dexamethasone, 0.2 mM ascorbic acid, and 10 mM ␤-glycerol phosphate (Sigma)] or adipogenic supplement [0.5 M hydrocortisone, 500 M isobutylmethylxanthine, and 60 M indomethacin (Sigma)]. The differentiation medium was changed every 3 days until day 21. To assess mineral deposition, cells were rinsed with PBS, fixed in cold methanol (Ϫ20°C) for 10 min, briefly washed twice with distilled H2O (dH 2O), stained with 2% alizarin red S (pH 4.1; Sigma) for 15 min, and washed five times with dH 2O. To assess lipid droplet formation, cells were rinsed with PBS, fixed in 10% formalin (Sigma) for 1 h, briefly washed twice with dH2O, stained with a freshly prepared oil red O solution for 15 min, and washed with dH2O. The oil red O solution was prepared by mixing three parts of an oil red O stock solution [0.5% in isopropanol (Sigma)] with two parts of dH2O and filtering it through a 0.45-m-pore filter.
Intracavernosal injection of Ad5RSVeNOS-transduced rMSCs into aged rats and histology. rMSCs were transduced with Ad5RSVeNOS at MOI 300 for 48 h. The virus-containing culture medium was removed, and the cells were washed three times with PBS. These Ad5RSVeNOS-transduced rMSCs were then harvested with trypsin-EDTA and washed with PBS, and a cell suspension at a concentration of 12,500 cells/l was prepared in PBS. The cell suspension was put on ice until the rats were anesthetized. All in vivo experiments were performed on 25-mo-old male Brown Norway rats in accordance with institutional and National Institutes of Health guidelines for the care and use of laboratory animals. These aged rats were anesthetized with pentobarbital sodium (30 mg/kg, ip; Sigma) and placed in a supine position on a heated surgical table. Under sterile conditions, the penis was exposed and 40 l of cell suspension or 40 l of PBS were injected into the corpus cavernosum with a syringe and a 25-gauge needle. A total of 500,000 cells or 40 l of PBS was injected into each rat, and six rats per group were used in the experiment. Immediately before injection, blood drainage via the dorsal vein was halted by circumferential compression of the penis at the base with an elastic band. The compression was released 1 min after the injection. The rat was monitored until recovery from the anesthetic and then returned to the animal care facility. At 7 days after intracavernosal injection of Ad5RSVeNOS-transduced rMSCs or PBS, rats were deeply anesthetized with pentobarbital sodium (80 mg/kg, ip; Sigma) and intracardiacally perfused with 200 ml of ice-cold PBS. For immunohistochemistry, the penis was removed, cut into 5-mm sagittal fragments, and fixed in ice-cold 4% paraformaldehyde in PBS (US Biochemicals, Cleveland, OH) at 4°C overnight. The penis was then transferred to 30% sucrose in PBS (Sigma) in a 50-ml conical tube at 4°C overnight. The tissue was embedded in OCT compound (Triangle Biomedical Sciences, Durham, NC), snap frozen in liquid nitrogen, and stored at Ϫ70°C. Penile cross sections (5 m) were then prepared with a cryostat and mounted on Superfrost Plus slides (Fisher Scientific, Pittsburgh, PA). To prepare homogenates for Western blot analysis, the penis was excised, quickly frozen in liquid nitrogen, and stored at Ϫ70°C. Cavernosal tissue was then homogenized (Polytron, Brinkmann Instruments, Westbury, NY) in an ice-cold buffer (5 mM HEPES, pH 7.9, 26% glycerol, 1.5 mM MgCl 2, 0.2 mM EDTA, 0.5 mM DTT, 0.5 mM phenylmethylsulfonyl fluoride, and 300 mM NaCl), incubated on ice for 30 min, and centrifuged twice at 15,000 g at 4°C for 20 min, and the supernatant was collected. Protein content of the homogenate was quantified colorimetrically using the bicinchoninic acid protein assay (Pierce).
Statistical analysis. Values are means Ϯ SE and were analyzed statistically using a t-test or a one-way analysis of variance followed by post hoc analysis with Tukey's test.
RESULTS
Adenoviral transduction of ex vivo expanded rMSCs.
The effectiveness of adenoviral-mediated gene transfer into ex vivo expanded rMSCs was examined using rMSCs transduced with Ad5RSVeNOS at MOI 300, 1,000, 1,500, and 2,000. After 48 h, the cells were immunostained for eNOS expression, and transduction efficiency was observed to be Ͼ60% at MOI 300 and Ͼ90% at MOI 2,000 (Fig. 1A) . Cell viability was determined to be Ͼ90% at all MOI. Furthermore, expression of nuclear-targeted ␤-galactosidase in Ad5RSVntlacZ-transduced rMSCs was also assessed by X-gal staining.
In these experiments, MOI 50-300 was used, and at MOI 300, transduction efficiency was Ͼ90% (Fig. 2) . Cell viability was determined to be Ͼ90% at all MOI studied.
Western blot analysis for eNOS. eNOS expression was assessed in Ad5RSVeNOS-transduced rMSCs, Ad5RSVntlacZ-transduced rMSCs, and control rMSCs using Western blot analysis. No constitutive eNOS expression was detected in control rMSCs or Ad5RSVntlacZ-transduced rMSCs. Expression of eNOS was detected in Ad5RSVeNOS-transduced rMSCs, and dose-dependent eNOS transgene expression was also observed. Furthermore, eNOS expression levels are much higher in Ad5RSVeNOS-transduced rMSCs than in endothelial cells (Fig. 1B) .
Differentiation of Ad5RSVeNOS-transduced rMSCs in vitro. To investigate whether rMSCs retain multidifferentiation potential after adenoviral-mediated eNOS gene transfer, rMSCs were transduced with Ad5RSVeNOS at MOI 2,000 for 48 h and further grown in the presence of differentiation media. After exposure to osteogenic medium, mineral deposition was observed (Fig. 3, A-D) . Moreover, after exposure to adipogenic medium, the cells exhibited lipid droplets. Thus the osteogenic and adipogenic potential of Ad5RSVeNOS-transduced rMSCs was retained. The percentage of differentiated cells in control and Ad5RSVeNOS-transduced rMSCs was counted. The percentage of differentiated osteoblasts in control and Ad5RSVeNOS-transduced rMSCs was 59 Ϯ 2% and 59 Ϯ 3% (mean Ϯ SE, n ϭ 3, P Ͼ 0.05 by t-test), respectively. The percentage of differentiated adipocytes in control and Ad5RSVeNOS-transduced rMSCs was 37 Ϯ 1% and 35 Ϯ 2% (n ϭ 3, P Ͼ 0.05 by t-test), respectively. Therefore, these data indicate that there is no statistical difference between the differentiation potential of control and Ad5RSVeNOS-transduced rMSCs in osteogenic or adipogenic medium.
The expression of eNOS in these differentiated cells was also assessed. The percentage of eNOS-positive cells at day 21 in osteogenic medium-treated cells was 9 Ϯ 3% (mean Ϯ SE, n ϭ 3). The percentage of eNOSpositive cells at day 21 in adipogenic medium-treated cells was 33 Ϯ 2% (n ϭ 3). The differentiated osteoblasts and adipocytes are still positive for eNOS (Fig. 3,  E and F) .
Persistence of adenoviral-mediated eNOS transgene expression in vitro. To study the persistence of eNOS transgene expression in vitro, rMSCs were transduced with Ad5RSVeNOS at MOI 300 for 48 h. The viruscontaining culture medium was then removed. The cells were washed three times with PBS and further incubated in low-serum medium (␣-MEM with 2% fetal bovine serum, 100 U/ml penicillin, 100 g/ml streptomycin, 25 ng/ml amphotericin B, and 2 mM L-glutamine) for 21 days. The low-serum medium was changed every 2-3 days, and eNOS expression was assessed at various times after transduction. The number of cells expressing eNOS was Ͼ60% at day 2 and Ͼ30% at day 21 (Fig. 4) .
Intracavernosal injection of Ad5RSVeNOS-transduced rMSCs. The purpose of this in vivo study was to assess the capability of Ad5RSVeNOS-transduced rMSCs to express eNOS in the rat corpus cavernosum. For these experiments, 5 ϫ 10 5 Ad5RSVeNOS-transduced rMSCs (MOI 300) were injected into the corpus cavernosum of aged Brown Norway rats. At 7 days after intracavernosal injection, significant numbers of the transplanted eNOS-positive Ad5RSVeNOS- Fig. 3 . Photomicrograph showing that Ad5RSVeNOS-transduced rMSCs retain multipotentiality in culture and that differentiated cells still express eNOS. rMSCs were transduced with Ad5RSVeNOS at MOI 2,000 for 2 days. Cells were then induced to differentiate into osteoblast or adipocyte lineage for 21 days and stained with alizarin red S for mineral deposition or oil red O for lipid droplet formation or immunostained for eNOS expression. A: Ad5RSVeNOS-transduced rMSCs stained with alizarin red S. B: Ad5RSVeNOS-transduced rMSCs treated with osteogenic medium for 21 days and then stained with alizarin red S. C: Ad5RSVeNOS-transduced rMSCs stained with oil red O. D: Ad5RSVeNOS-transduced rMSCs treated with adipogenic medium for 21 days and then stained with oil red O. E: Ad5RSVeNOS-transduced rMSCs treated with osteogenic medium for 21 days and then immunostained for eNOS expression. F: Ad5RSVeNOS-transduced rMSCs treated with adipogenic medium for 21 days and then immunostained for eNOS expression. Arrows, eNOS-positive brown differentiated osteoblasts; arrowheads, eNOSpositive brown differentiated adipocytes. Magnification ϫ500. transduced rMSCs were identified within the proximal, mid, and distal corporal sinusoids. Immunohistochemical localization of eNOS was qualitatively more abundant in the endothelium of the rats transplanted with the rMSCs expressing eNOS (Fig. 5) . Western blot analysis further demonstrated that the expression of eNOS protein was increased in the cavernosal tissue 7 days after intracavernosal injection of Ad5RSVeNOS-transduced rMSCs (Fig. 5) . To determine whether overexpression of cavernosal eNOS protein would influence erectile function in aged rats in vivo, intracavernosal pressure changes in response to cavernosal nerve stimulation were measured as previously described (4) (5) (6) 14) . The changes in intracavernosal pressure were determined 7 days after treatment with PBS, Ad5RSVntlacZ-transduced rMSCs (MOI 300), and Ad5RSVeNOS-transduced rMSCs (MOI 300). The increase in intracavernosal pressure and total area under the erectile curve (cmH 2 O ⅐ s, AUC) in response to cavernosal nerve stimulation (5 V) were significantly greater in the Ad5RSVeNOS-transduced rMSCtreated aged rats (73.4 Ϯ 6.4 cmH 2 O and 6,078 Ϯ 289 AUC, n ϭ 6; Fig. 5 ) than in the PBS-treated aged rats (48.8 Ϯ 5.1 cmH 2 O and 3,026 Ϯ 155 AUC, P Ͻ 0.05, n ϭ 6) or the Ad5RSVntlacZ-transduced rMSC-treated rats (46.2 Ϯ 4.8 cmH 2 O and 2,861 Ϯ 329 AUC, P Ͻ 0.05, n ϭ 5).
DISCUSSION
In this study, we demonstrate that ex vivo expanded rMSCs can be transduced with a replication-deficient recombinant adenoviral vector containing the eNOS gene, a potentially important candidate for cardiovascular gene therapy (5, 13, 14, 22, 37) . We also demonstrate that adenoviral-mediated eNOS gene transfer into rMSCs is dose dependent, and the eNOS transgene expression in vitro can persist for Ն21 days. We further demonstrate that rMSCs retained multipotential differentiation capability after adenoviral-mediated eNOS gene transfer. The present study also shows that intracavernosal injection of Ad5RSVeNOS-transduced rMSCs increased cavernosal eNOS expression and improved erectile function in the aged rat penis.
It was previously reported that ex vivo expanded human MSCs (hMSCs) can be transduced with adenoviral vector containing the reporter gene lacZ (19, 46) . However, the data are not consistent. In one study, only a small population of hMSCs (ϳ20%) were transduced with the adenoviral vector. Neither the MOI (range 250-2,000) nor the period of time the cells were exposed to the virus (Ͼ6 h) caused a variation in the percentage of transduced cells (19) . In the other study, adenoviral-mediated gene transfer to hMSCs was shown to be dose dependent. The transduction efficiency at MOI 1,000-1,500 was Ͼ90%, and the RSV promoter was more active than the cytomegalovirus promoter in expressing the lacZ gene in hMSCs (46) . In the present experiments, we demonstrate that adenoviral-mediated gene transfer to rMSCs is dose dependent and that the RSV promoter can be used to express the reporter gene ntlacZ and the therapeutic gene eNOS.
For gene therapy in vascular diseases such as erectile dysfunction and pulmonary hypertension, in vivo and ex vivo strategies have been used to deliver therapeutic gene products such as NO and calcitonin generelated peptide (CGRP) into the corpus cavernosum or the lung. In vivo gene therapy strategy includes direct transfer of adenovirus encoding eNOS or CGRP, which was mainly carried out in our laboratory. Previous studies demonstrate that direct in vivo injection of adenovirus containing eNOS or prepro-CGRP attenuated pulmonary hypertension and augmented erectile responses in the rat and mouse (4-6, 13, 14) . However, the disadvantage of this strategy includes a local in- Fig. 4 . A: effect of time on eNOS expression in Ad5RSVeNOS-transduced rMSCs. rMSCs were transduced with Ad5RSVeNOS at MOI 300 for 2 days. Virus-containing culture medium was removed, and cells were washed 3 times with PBS and further incubated in low-serum medium. Low-serum medium was changed every 2-3 days until day 21. Cells were immunostained for eNOS expression at days 2, 4, 7, 14 , and 21, and percentage of cells expressing eNOS was quantified. Values are means Ϯ SE (n ϭ 3). *P Ͼ 0.05 vs. day 2; **P Ͼ 0.05 vs. day 2 or day 4; ***P Ͻ 0.01 vs. day 2 or day 4; P Ͼ 0.05 vs. day 7; ****P Ͻ 0.001 vs. An ex vivo gene therapy approach is direct injection of eNOS-or CGRP gene-modified carrier cells into an organ. The therapeutic gene-modified carrier cells are used as vehicles to locally deliver therapeutic gene products such as NO and CGRP. The major advantage of this strategy is that the carrier cells can be manipulated ex vivo. However, the criteria for choosing carrier cells are very strict and require that the cells can be easily isolated and ex vivo expanded. It is also important that the cells efficiently express transgenes such as eNOS and CGRP and that the cells survive for a long period of time in vivo and do not elicit a strong immune response. In previous studies, only endothelial cells have been employed in cell transplantation experiments (48) . In this previous study, as a first step toward a cell-based gene therapy for erectile dysfunction, autologous microvessel endothelial cells were transplanted into the rat corpus cavernosum. After 2-15 days, the transplanted endothelial cells adhered and persisted in corporal sinusoids. However, another study demonstrates that adenoviral-mediated gene transfer of eNOS to human endothelial cells inhibits endothelial cell proliferation (49) . A major advantage of using endothelial cells is that they can be used for autologous transplantation. However, inasmuch as endothelial cells are difficult to obtain from human patients and difficult to manipulate in culture, the use of these cells is limited. Furthermore, transplantation of allogeneic endothelial cells from human donor or human fetus will elicit host immune rejection and can raise ethical issues.
To explore an alternative approach, we propose the use of MSCs as carriers for ex vivo gene therapy for erectile dysfunction and pulmonary hypertension, because these cells fulfill the criteria for carrier cells. First, hMSCs can be easily obtained from the bone marrow of human patients by adherence to cell culture plastic, readily ex vivo expanded, and efficiently gene engineered (10, 15, 16, 18, 19, 28, 38, 43, 46) . Therefore, gene-modified ex vivo expanded MSCs can be used as carrier cells to locally deliver a therapeutic gene product after autologous transplantation. In an intracerebral infusion study, rMSCs were transduced with retroviruses encoding tyrosine hydroxylase and GTP cyclohydrolase I. The cells synthesized L-DOPA in vitro and retained their multipotentiality after retroviral transduction. The cells were injected into the striatum of 6-hydroxydopamine-lesioned rats, and the transgene expression lasted for 9 days. There was a significant reduction in apomorphine-induced head rotation in the rat, and the cells engrafted and survived for Ն87 days (43) . Second, MSCs do not elicit a host immune rejection response and can survive for a long period of time in vivo after autologous transplantation (17, 25, 38, 41) . Finally, MSCs are capable of differentiating into osteoblasts, chondrocytes, adipocytes, myocytes, and other cell types (21, 24, 33, 39, 45) . Therefore, these cells can be used in adult stem cell-based therapy for the regeneration of mesenchymal tissues such as bone, cartilage, fat, and muscle. In one study, hMSCs were transplanted in utero into the sheep fetus. The cells engrafted in the fetus and persisted in multiple tissues in the neonate for as long as 13 mo and differentiated into chondrocytes, adipocytes, myocytes, cardiomyocytes, bone marrow stromal cells, and thymic stroma (33) . In another study, swine MSCs were implanted into the infarct area of a swine myocardial infarct model. Microscopic and sonomicrometry analysis demonstrated that implantation of autologous MSCs results in sustained engraftment, myogenic differentiation, and improved cardiac function (45) . Therefore, eNOS-or CGRP-modified MSCs should be able to locally deliver therapeutic gene products such as NO and CGRP after autologous transplantation, and the cells may also be able to replace injured host cells after in Fig. 5 . Immunohistochemical localization of eNOS in PBS-treated (A) and Ad5RSVeNOS-transduced rMSC-treated (B) rats. The rat was killed 7 days after intracavernosal injection of Ad5RSVeNOS-transduced rMSCs (MOI 300) or PBS, and penile tissue was immunostained with anti-eNOS antibody to identify eNOS-positive Ad5RSVeNOS-transduced rMSCs. Brown staining and arrowheads denote presence of eNOS-positive cells. C: penile tissue from a rat after intracavernosal injection of Ad5RSVeNOS-transduced rMSCs stained with an isotype antibody control, used to identify corporal anatomic detail, including sinusoids, endothelial cell (ec), and cavernosal smooth muscle cell (CSMC). Magnification ϫ250. D: Western blot analysis of eNOS protein expression in cavernosal tissue from PBS-treated (lanes 1 and 2) and Ad5RSVeNOS-transduced rMSC-treated (lanes 3 and 4) rats. Analysis for ␤-tubulin was carried out to ensure that sample loading was similar in all lanes. E: representative intracavernosal pressure trace after cavernosal nerve stimulation at 5 V for 1 min in PBS-treated (I), Ad5RSVlacZ-transduced rMSC-treated (II), and Ad5RSVeNOS-transduced rMSC-treated (III) aged rats.
vivo differentiation under the influence of local tissue microenvironment.
To combine gene therapy and adult stem cell procedures, we are pursuing the potential of developing an improved therapy for erectile dysfunction and pulmonary hypertensive disorders using MSCs transduced with therapeutic genes such as eNOS and prepro-CGRP. Our initial in vivo study in aged rats indicates that intracavernosal injection of Ad5RSVeNOS-transduced rMSCs increased the expression of eNOS in the corpus cavernosum. We have shown that injection of adenoviral vectors coding for eNOS and CGRP improves erectile function, and from our preliminary experiments with Ad5RSVeNOS-transduced rMSCs, we hypothesize that injection of eNOS-transduced rMSCs will improve erectile function and may have the advantage of causing less inflammation (3-6, 13, 14) . Future erectile function time course studies and an evaluation of cavernosal nerve-mediated and agonist-induced erectile responses will be undertaken to determine whether eNOS-expressing rMSCs improve erectile function over long periods of time in aged rats.
In summary, the results of the present study show for the first time the successful adenoviral gene transfer of eNOS to ex vivo expanded rMSCs. The Ad5RSVeNOS-transduced rMSCs produced high levels of eNOS expression that persisted in culture for Ͼ21 days. The cells retained their multipotential differentiation capability after adenoviral-mediated eNOS gene transfer. Moreover, intracavernosal injection of Ad5RSVeNOS-transduced rMSCs increased the expression of eNOS in the corpus cavernosum and improved erectile function in aged rats. These data suggest that this novel adult stem cell-based gene therapy strategy may represent a new form of therapy for the treatment of disorders in which eNOS activity is reduced.
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